These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3019993)

  • 1. Prolonged sodium stibogluconate therapy in Indian kala-azar.
    Jha TK; Sharma VK
    J Assoc Physicians India; 1986 Jul; 34(7):469-71. PubMed ID: 3019993
    [No Abstract]   [Full Text] [Related]  

  • 2. Kala-azar: unresponsiveness to prolonged sodium stibogluconate therapy.
    Bhattacharya D; Majhi TK; Dutta RK
    J Assoc Physicians India; 1987 Jul; 35(7):543. PubMed ID: 2828305
    [No Abstract]   [Full Text] [Related]  

  • 3. Complications of kala azar and its treatment in Kenya.
    Chunge CN; Gachihi G; Chulay JD; Spencer HC
    East Afr Med J; 1984 Feb; 61(2):120-7. PubMed ID: 6088210
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium antimony resistant cases of kala-azar in and around Patna (south Bihar).
    Sehgal PN; Murmu C; Chatteyee AK
    J Commun Dis; 1988 Jun; 20(2):161-2. PubMed ID: 2853714
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antimony content of the thyroid of man and animals undergoing visceral leishmaniasis treatment with the organic compound of antimony, stibogluconate sodium].
    Fuzaĭlov IuM
    Med Parazitol (Mosk); 1982; 51(1):62-5. PubMed ID: 6278277
    [No Abstract]   [Full Text] [Related]  

  • 6. ECG changes in prolonged treatment of kala-azar with antimony compounds.
    Pandey AK; Kumar M; Thakur CP
    J Assoc Physicians India; 1988 Jun; 36(6):398-9. PubMed ID: 2846508
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP; Singh AN
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.
    Thakur CP; Kumar K; Sinha PK; Mishra BN; Pandey AK
    Br Med J (Clin Res Ed); 1987 Oct; 295(6603):886-7. PubMed ID: 2823955
    [No Abstract]   [Full Text] [Related]  

  • 9. Observations on the effect of verapamil with sodium stibogluconate in kala azar.
    Thakur CP; Kumar M
    Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response of Kenyan kala-azar to treatment with sodium stibogluconate.
    Rees PH; Kager PA; Wellde BT; Hockmeyer WT
    Am J Trop Med Hyg; 1984 May; 33(3):357-61. PubMed ID: 6329010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
    Bourée P; Anciaux ML; Taugourdeau P
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):607-10. PubMed ID: 3003657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post kala-azar dermal leishmaniasis: the Kenyan experience.
    Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
    East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of visceral leishmaniasis using sodium stibogluconate in a dose of 15 mg antimony/kg body weight twice daily for 30 days: a preliminary report.
    Chunge CN; Gachihi G; Mugambi M; Chulay JD; Spencer HC
    East Afr Med J; 1984 Jul; 61(7):570-4. PubMed ID: 6100588
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.
    Thakur CP; Kumar M; Kumar P; Mishra BN; Pandey AK
    Br Med J (Clin Res Ed); 1988 Jun; 296(6636):1557-61. PubMed ID: 2840172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocyte population and immunoglobulins in Indian kala-azar in response to chemotherapy.
    Neogy AB; Nandy A; Dastidar BG; Chowdhury AB
    Acta Trop; 1986 Sep; 43(3):237-44. PubMed ID: 2877550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of visceral leishmaniasis.
    Thakur CP
    J Assoc Physicians India; 1985 May; 33(5):379-80. PubMed ID: 2995305
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis.
    Thakur CP; Kumar K
    Indian J Med Res; 1990 Mar; 91():144-8. PubMed ID: 2160914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients.
    Kager PA; Rees PH; Manguyu FM; Bhatt KM; Wellde BT; Hockmeyer WT; Lyerly WH
    Trop Geogr Med; 1984 Mar; 36(1):21-35. PubMed ID: 6328709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.